Trial
NCT03367819
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Sanofi
Collaborators
—
Condition
Prostate Cancer
Intervention
Isatuximab SAR650984
Why stopped
The study was stopped after interim analysis indicated that overall result was not sufficient to satisfy per-protocol criteria to move forward in metastatic, castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) cohorts.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-16